
Nirmatrelvir/Ritonavir Reduces Post-Acute Mortality in Immunocompromised COVID-19 Patients
A recent study analyzing the impact of nirmatrelvir/ritonavir (Paxlovid) in immunocompromised patients hospitalized with COVID-19 found that the antiviral therapy was associated with a significantly reduced risk of post-acute inpatient death. Conducted …